Turbogen CEO Gilboa reports 683,906-share stake
Turbogen Ltd. (TRBG) reported the initial holdings of Chief Executive Officer Yaron Gilboa in a Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Turbogen Ltd. (TRBG) reported the initial holdings of Chief Executive Officer Yaron Gilboa in a Form 3. Gilboa holds 683,906 ordinary shares directly, consisting of ordinary shares and time-vesting restricted share units. He also holds several option grants to acquire additional ordinary shares at exercise prices between $1.29 and $6.18 per share with expirations from 2029 through 2036, all reported as unexercised as of late August 2026.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Gilboa Yaron
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share option (right to buy) F3, F2 | -- | -- | -- |
| holding | Share option (right to buy) F5, F4 | -- | -- | -- |
| holding | Share option (right to buy) F7, F6 | -- | -- | -- |
| holding | Share option (right to buy) F9, F8 | -- | -- | -- |
| holding | Share option (right to buy) F11, F10 | -- | -- | -- |
| holding | Share option (right to buy) F13, F12 | -- | -- | -- |
| holding | Ordinary shares F1 | -- | -- | -- |
Holdings After Transaction:
Share option (right to buy) — 1,482,495 contracts (Direct);
Ordinary shares — 683,906 shares (Direct)
Footnotes (13)
- F1. Represents (i) 375,590 ordinary shares, no par value per share, (ii) 143,316 restricted share units ("RSUs") granted on November 26, 2025, 83.3% of which vested and the remaining 16.6% vest in equal quarterly installments of 8.3% thereafter, of which 119,428 RSUs have vested and 23,888 remain unvested as of August 25, 2026; and (iii) 165,000 RSUs granted on April 29, 2026, 41.6% of which and vested and the remaining 58.3% vest in equal quarterly installments of 8.33% thereafter, of which 68,750 RSUs have vested and 96,250 remain unvested as of August 25, 2026. Each RSU represents the right to receive one ordinary share.
- F2. A total of 33,300 options were granted on December 10, 2019 and vested in equal quarterly installments of 6.25% retroactively beginning on June 1, 2018. As of August 25, 2026, 33,300 options are fully vested and none have been exercised into ordinary shares. Number of ordinary shares issuable upon exercise of the options reflects adjustments to the Company's issued and outstanding share capital between 2021 and 2023.
- F3. The options were granted with an exercise price of NIS 4.16 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $1.39 per share.
- F4. A total of 5,125 options were granted on January 3, 2021 and were fully vested on the date of grant. As of August 25, 2026, 5,125 options are fully vested and none have been exercised into ordinary shares. Number of ordinary shares issuable upon exercise of the options reflects adjustments to the Company's issued and outstanding share capital between 2021 and 2023.
- F5. The options were granted with an exercise price of NIS 3.86 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $1.29 per share.
- F6. A total of 130,248 options were granted on January 26, 2023 and vested in equal quarterly installments of 8.3% retroactively beginning on December 31, 2021. As of August 25, 2026, 130,248 options are fully vested and none have been exercised into ordinary shares. Number of ordinary shares issuable upon exercise of the options reflects adjustments to the Company's issued and outstanding share capital between 2021 and 2023.
- F7. The options were granted with an exercise price of NIS 10.50 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $3.50 per share.
- F8. A total of 398,076 options were granted on December 31, 2023 and vested in equal quarterly installments of 8.3% retroactively beginning on December 31, 2022. As of August 25, 2026, 398,076 options are fully vested and none have been exercised into ordinary shares. Number of ordinary shares issuable upon exercise of the options reflects adjustments to the Company's issued and outstanding share capital between 2021 and 2023.
- F9. The options were granted with an exercise price of NIS 5.38 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $1.79 per share.
- F10. A total of 398,076 options were granted on November 26, 2025 and vested in equal quarterly installments of 8.3% retroactively beginning on December 31, 2023. As of August 25, 2026, 331,730 options are fully vested and none have been exercised into ordinary shares.
- F11. The options were granted with an exercise price of NIS 10.16 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $3.39 per share.
- F12. A total of 165,000 options were granted on April 29, 2026 and vested as follows: 33.3% vested on April 1, 2026, and the remaining 66.7% vest in equal quarterly installments of approximately 8.33% of the original grant beginning July 1, 2026. As of August 25, 2026, 68,750 options are fully vested and none have been exercised into ordinary shares.
- F13. The options were granted with an exercise price of NIS 18.5 per share. For purposes of this Form 3, the exercise price has been converted into U.S. dollars using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026, resulting in an exercise price of $6.18 per share.
Key Figures
Direct ordinary shares held: 683,906 shares
RSUs granted November 26, 2025: 143,316 RSUs
RSUs granted April 29, 2026: 165,000 RSUs
+5 more
8 metrics
Direct ordinary shares held
683,906 shares
Direct ordinary share holdings including RSUs as of late August 2026
RSUs granted November 26, 2025
143,316 RSUs
119,428 vested and 23,888 unvested as of August 25, 2026
RSUs granted April 29, 2026
165,000 RSUs
68,750 vested and 96,250 unvested as of August 25, 2026
Option exercise price
$1.39 per share
Share options over 335,497 underlying ordinary shares expiring December 10, 2029
Option exercise price
$1.29 per share
Share options over 51,634 underlying ordinary shares expiring January 3, 2031
Option exercise price
$3.50 per share
Share options over 131,225 underlying ordinary shares expiring January 26, 2033
Option exercise price
$1.79 per share
Share options over 401,063 underlying ordinary shares expiring December 31, 2033
Option exercise price
$6.18 per share
Share options over 165,000 underlying ordinary shares expiring April 29, 2036
Key Terms
restricted share units ("RSUs"), exercise price, fully vested, ordinary shares, +1 more
5 terms
exercise price financial
"The options were granted with an exercise price of NIS 4.16 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"As of August 25, 2026, 33,300 options are fully vested and none have been exercised"
Form 3 regulatory
"For purposes of this Form 3, the exercise price has been converted into U.S. dollars"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position did Turbogen Ltd. (TRBG) disclose in this Form 3?
The filing discloses that Chief Executive Officer Yaron Gilboa is a reporting person, with direct holdings in ordinary shares, restricted share units, and multiple option grants of Turbogen Ltd. He is not reported as a ten percent owner in this document.
What stock options does Turbogen (TRBG) CEO Yaron Gilboa hold and at what exercise prices?
Gilboa holds options over 335,497, 51,634, 131,225, 401,063, 398,076 and 165,000 underlying ordinary shares at exercise prices of $1.39, $1.29, $3.50, $1.79, $3.39 and $6.18 per share, with expirations between 2029 and 2036.
Are Yaron Gilboa’s Turbogen (TRBG) options and RSUs vested or exercised?
As of August 25, 2026, the footnotes state that all listed options are fully vested or vesting pursuant to stated schedules and that none have been exercised into ordinary shares. RSUs from the 2025 and 2026 grants are partially vested, with specific vested and unvested amounts disclosed.
Does this Turbogen (TRBG) Form 3 report any recent insider buying or selling?
No. The Form 3 is an initial statement of beneficial ownership and lists holdings only. The structured data show no reported insider purchases, sales, exercises, gifts, or other disposition transactions in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
